{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:11:21Z","timestamp":1776204681807,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:36:26Z","timestamp":1775712986000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials"],"prefix":"10.1016","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.009_b0005","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0010","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III Titan study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0015","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/cncr.34910","article-title":"Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone\u2010sensitive prostate cancer","volume":"129","author":"Nierengarten","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.03.009_b0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.009_b0025","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0035","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.03.009_b0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.eururo.2025.05.037","article-title":"Postprogression survival of patients with metastatic hormone-sensitive prostate cancer who received darolutamide or placebo in combination with docetaxel and androgen deprivation therapy: post hoc analysis of the Phase 3 ARASENS trial","volume":"88","author":"Grimm","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.009_b0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-023-00668-0","article-title":"Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy","volume":"27","author":"Afferi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.009_b0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.009_b0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0060","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2025.43.16_suppl.5004","article-title":"Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial","volume":"43","author":"Morgans","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.euo.2026.03.009_b0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.09.035","article-title":"The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies","volume":"87","author":"Beer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.009_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euo.2024.04.010","article-title":"Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED)","volume":"8","author":"Sentana-Lledo","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41391-022-00529-2","article-title":"Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study","volume":"26","author":"Roy","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.009_b0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","article-title":"Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials","volume":"139","author":"Olivier","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2026.03.009_b0085","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.009_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the functional assessment of cancer therapy\u2014prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2026.03.009_b0100","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.31973","article-title":"Meaningful differences and validity for the NCCN\/FACT\u2010P Symptom Index: an analysis of the ALSYMPCA data","volume":"125","author":"Beaumont","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.03.009_b0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1536867X20976311","article-title":"merlin\u2014a unified modeling framework for data analysis and methods development in Stata","volume":"20","author":"Crowther","year":"2020","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"10.1016\/j.euo.2026.03.009_b0110","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.009_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers14010147","article-title":"Assessment of health-related quality of life in patients with advanced prostate cancer-current state and future perspectives","volume":"14","author":"Kretschmer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.03.009_b0120","unstructured":"EAU guidelines. Edn. Presented at the EAU Annual Congress Madrid 2025."},{"key":"10.1016\/j.euo.2026.03.009_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102914","article-title":"Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review","volume":"78","author":"Osanto","year":"2024","journal-title":"EClinicalmedicine"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:37:53Z","timestamp":1776202673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"alternative-id":["S2588931126000672"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}